In Brief: Possis Medical
This article was originally published in The Gray Sheet
Executive Summary
Possis Medical: FDA grants "conditional approval" for Phase II studies of Possis' AngioJet rapid thrombectomy system for use in removing blood clots from coronary arteries and bypass grafts, the firm says. The trials are expected to involve "a minimum" of 15 investigational sites and 570 patients...